688526 科前生物
2024/03 - 三个月2023/122022/122021/122020/12

盈利能力分析
净资产收益率 ROE (%)2.25510.79912.31619.47323.400
总资产报酬率 ROA (%)1.8788.73810.09216.69819.981
投入资产回报率 ROIC (%)2.0149.52111.17218.44015.691

边际利润分析
销售毛利率 (%)66.63872.09373.61179.80582.782
营业利润率 (%)49.10243.14846.61259.92762.179
息税前利润/营业总收入 (%)41.47636.76840.26753.97257.765
净利润/营业总收入 (%)42.49137.17640.86351.73453.106

收益指标分析
经营活动净收益/利润总额(%)87.372112.82199.50298.50198.213
价值变动净收益/利润总额(%)3.7712.0411.7350.7770.766
营业外收支净额/利润总额(%)-0.615-0.339-0.023-0.144-0.895

偿债能力分析
流动比率 (X)3.8803.3844.1053.5786.950
速动比率 (X)3.6503.1933.8343.3576.750
资产负债率 (%)15.47517.84520.30715.33912.935
带息债务/全部投入资本 (%)8.0949.7289.0423.393--
股东权益/带息债务 (%)1,113.349910.127970.4822,777.6433,102.180
股东权益/负债合计 (%)545.932460.132392.198551.875673.088
利息保障倍数 (X)-5.662-5.897-6.356-9.197-14.956

营运能力分析
应收账款周转天数 (天)141.363110.821106.33968.6530.000
存货周转天数 (天)191.694190.461189.534145.3590.000